SCHEMBL16583296

SCHEMBL16583296

CC[C@@H](C(=O)Nc1cccc(Cl)c1C(=O)Nc1ccccc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.42
PTGS2 P35354 1/20 0.41
ITGB1 P05556 9/20 0.41
ITGA4 P13612 9/20 0.41
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
F2R P25116 1/20 0.40
CYP3A4 P08684 2/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
EGFR P00533 1/20 0.38
ITGA2 P17301 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16583297 1.00 KCNQ2 (0.42) KCNQ2PTGS2ITGB1ITGA4MAPT
SCHEMBL18188672 0.92 GAA (0.44) KCNQ2ITGB1ITGA4MAPTGAA
SCHEMBL18188669 0.92 GAA (0.44) KCNQ2ITGB1ITGA4MAPTGAA
SCHEMBL18188676 0.90 SMN1; SMN2 (0.41) MAPTMEN1KMT2ALMNAGAA
SCHEMBL18188679 0.90 SMN1; SMN2 (0.41) MAPTMEN1KMT2ALMNAGAA
SCHEMBL16583588 0.90 KCNQ2 (0.41) KCNQ2ITGB1ITGA4MAPTMEN1
SCHEMBL16583587 0.90 KCNQ2 (0.41) KCNQ2ITGB1ITGA4MAPTMEN1
SCHEMBL18188580 0.89 TAS1R3 (0.45) KCNQ2MAPTMEN1KMT2ALMNA
SCHEMBL18188581 0.89 TAS1R3 (0.45) KCNQ2MAPTMEN1KMT2ALMNA
SCHEMBL18188681 0.88 RAB9A (0.40) MAPTMEN1KMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3046563-B1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS PI3-KINASE INHIBITORS CALITOR SCIENCES LLC (US) 2019-05-29 EP disclosed
US-9670194-B2 Substituted aminopyrimidine compounds and methods of use CALITOR SCIENCES, LLC (US) 2017-06-06 US disclosed
US-9518046-B2 Substituted aminopyrimidine compounds and methods of use CALITOR SCIENCES, LLC (US) 2016-12-13 US disclosed
US-20160318913-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-11-03 US disclosed
US-20150087663-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087663-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, MYD88 KCNQ2 3650/4885PTGS2 959/4885ITGB1 3180/4885
US-20160318913-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, MYD88 KCNQ2 3669/4885PTGS2 972/4885ITGB1 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.